Delving into the Latest Updates on Sichuan Cunde Therapeutics Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Endocrinology and Metabolic Disease

TCR-T Cell therapy

Therapeutic vaccine

Cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Immune System Diseases	2
Endocrinology and Metabolic Disease	1
Infectious Diseases	1

Top 5 Drug Type	Count

TCR-T Cell therapy	2
Cell therapy	1
Therapeutic vaccine	1

Top 5 Target	Count

TCR(T-cell receptor)	2
IL-1R x MMPs	1

主要目的：评估CUD005注射液在肝硬化患者中的安全性和耐受性、确定最大耐受剂量（MTD），并评价单次剂量治疗的剂量限制性毒性（DLT）。次要目的：初步评估CUD005注射液在肝硬化患者中的逆转肝硬化的初步疗效；评估CUD005注射液在肝硬化患者中血清标志物的变化。

[Translation]

Primary objective: To evaluate the safety and tolerability of CUD005 injection in patients with cirrhosis, determine the maximum tolerated dose (MTD), and evaluate the dose-limiting toxicity (DLT) of single-dose treatment. Secondary objective: To preliminarily evaluate the preliminary efficacy of CUD005 injection in reversing cirrhosis in patients with cirrhosis; to evaluate the changes in serum markers of CUD005 injection in patients with cirrhosis.

Start Date26 Jul 2024

Sponsor / Collaborator

Sichuan Cunde Therapeutics Co., Ltd.

CTR20241951

/ RecruitingPhase 1

评价CUD002注射液在难治性/耐药复发性卵巢癌受试者中的安全性、耐受性、有效性和药效动力学特征的开放、剂量递增Ⅰ期临床研究

[Translation] An open-label, dose-escalation Phase I clinical study to evaluate the safety, tolerability, efficacy, and pharmacodynamics of CUD002 injection in subjects with refractory/resistant recurrent ovarian cancer

主要目的：评价CUD002注射液在难治性/耐药复发性卵巢癌受试者中的安全性和耐受性，并确定最大耐受剂量/推荐扩展剂量；次要目的：评价CUD002注射液在难治性/耐药复发性卵巢癌受试者中的药效动力学、免疫原性特征；探索性目的：评估抗肿瘤疗效；分析肿瘤标记物与疗效指标的关系。

[Translation]

Primary purpose: To evaluate the safety and tolerability of CUD002 injection in subjects with refractory/resistant recurrent ovarian cancer and determine the maximum tolerated dose/recommended extended dose; Secondary purpose: To evaluate the pharmacodynamics and immunogenicity characteristics of CUD002 injection in subjects with refractory/resistant recurrent ovarian cancer; Exploratory purpose: To evaluate the anti-tumor efficacy; to analyze the relationship between tumor markers and efficacy indicators.

Start Date17 Jul 2024

Sponsor / Collaborator

Sichuan Cunde Therapeutics Co., Ltd.

100 Clinical Results associated with Sichuan Cunde Therapeutics Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Sichuan Cunde Therapeutics Co., Ltd.

Login to view more data

100 Deals associated with Sichuan Cunde Therapeutics Co., Ltd.

Login to view more data

100 Translational Medicine associated with Sichuan Cunde Therapeutics Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Phase 1 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CUD-005 ( IL-1R x MMPs )	Liver Cirrhosis More	Phase 1
CUD002	Recurrent ovarian cancer More	Phase 1
CN116640730 ( TCR )	Infectious Diseases More	Discovery
CN116769719 ( TCR )	Rare Diseases More	Discovery
CUD004	Liver Cancer More	Discontinued